Deutsche Bank analyst David Hoang initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating and $152 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- 3 Must-Watch Stocks with a ‘Perfect 10’ Smart Score
- Jazz Pharmaceuticals Appoints Renee Gala as New CEO
- Jazz Pharmaceuticals appoints Renee Gala as President, CEO
- Jazz Pharmaceuticals’ Promising Study on Zanidatamab for HER2-positive Breast Cancer
- Jazz Pharmaceuticals’ New Study on Zanidatamab: A Potential Game-Changer in Breast Cancer Treatment?